Last reviewed · How we verify
NCT06734481: SAPLIC
Effectiveness and Safety of Sodium Bicarbonate Pleural Lavage in the Treatment of Complex Pleural Effusion
NA trial testing Sodium bicarbonate pleural lavage in Complicated Pleural Effusion/ Empyema in 260 participants. Currently enrolling.
1 May 2026
Quick facts
| Lead sponsor | First Affiliated Hospital of Ningbo University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 260 |
| Start date | 1 April 2024 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 August 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Sodium bicarbonate pleural lavage — full drug profile →
- Saline pleural lavage — full drug profile →
Conditions studied
- Complicated Pleural Effusion/ Empyema — all drugs for Complicated Pleural Effusion/ Empyema →
Sponsor
First Affiliated Hospital of Ningbo University
Who can join
Adults 18 to 80, any sex, with Complicated Pleural Effusion/ Empyema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to evaluate the safety and efficacy of sodium bicarbonate pleural lavage in treating complex pleural effusion in adult. The main questions it aims to answer are: Will sodium bicarbonate pleural lavage reduce the failure rate of medical treatment (referral rate for surgery) for complicated pleural effusion？ Can sodium bicarbonate pleural lavage accelerating the rehabilitation of patients with complicated pleural effusion？ Will sodium bicarbonate pleural lavage improve the prognosis of patients with complicated pleural effusion? Participants will will undergo catheter placement for continuous drainage of pleural effusion. Once at least 200 mL of pleural effusion has been drained: Group A: Participants will receive a daily intrapleural injection of 200 mL of saline in 7 days; Group B: Participants will receive a daily intrapleural injection of 200 mL of 2.5% sodium bicarbonate in 7 days.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06734481
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other First Affiliated Hospital of Ningbo University trials
Trials by the same sponsor.
- NCT07347977 — Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk · NA · not yet recruiting
- NCT07171892 — Development and Validation of a Risk Prediction Model for Ischemic Stroke in Acute Myocardial Infarction Without Comorbi · not yet recruiting
- NCT07493629 — Immune Status and Disease Control of Inflammatory Airway Diseases · recruiting
- NCT07313904 — Effects of Environmental Fungal Exposure on Bronchial Asthma, ABPA and Bronchiectasis · recruiting
- NCT07030881 — Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therap · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06734481 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Ningbo University
- Last refreshed: 16 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06734481.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing